BIOGEN INC.

BIIB

Explore Our Financial Data > Companies > BIOGEN INC.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	BIIB
CIK	0000875045
SIC	2836
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Biological Products, Except Diagnostic Substances

Contact

Address	225 BINNEY STREET, CAMBRIDGE, MA, 02142
Website	biogen.com
Phone	7814642000
CEO	Christopher A. Viehbacher
Employees	8,720

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$10.07 billion
Pre-Tax Income	$1.90 billion
Net Income	$1.61 billion
Net Income to Common	$1.61 billion
EPS	$10.96

View All

Balance Sheet

Cash	$3.86 billion
Assets	$29.21 billion
Liabilities	$11.00 billion
Common Equity	$18.21 billion
Liabilities & Equity	$29.21 billion

View All

Cash Flow Statement

Net Income	$1.61 billion
Cash From Operating Activities	$2.45 billion
Cash From Investing Activities	$-158.00 million
Cash From Financing Activities	$-157.00 million
Change in Cash	$2.14 billion

View All

Calculations

NOPAT	$1.90 billion
EBITDA	$3.22 billion
Price to Earnings	$15.88
Price to Book	$1.40
ROE	9.31%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Bitcoin hoarding company Strategy remains in Nasdaq 100

Bitcoin hoarding giant Strategy clung to its place in the Nasdaq 100 on Friday, continuing its year-long stint in the benchmark ‌at a time where analysts have raised questions over its business ‌model. Some market watchers have suggested Strategy's pioneering business model of buying-and-holding bitcoin, which has spawned dozens of copycats, more closely resembles that of an investment fund. Nasdaq said Biogen, ‍CDW Corporation, Globalfoundries, Lululemon Athletica, On Semiconductor and Trade Desk were removed from the tech-heavy exchange's benchmark index.

Article Link

Analysts flag risks for Strategy at Nasdaq 100 index reshuffle

Bitcoin hoarding giant Strategy may be at risk of being removed from the Nasdaq 100 index at its annual reshuffle on Friday, amid questions over its business model that have weighed on its share price, some analysts flagged this week. After a sizzling rally that pushed its market capitalization to a peak of $128 billion earlier this ‌year, Strategy - which started out as software company MicroStrategy but pivoted to bitcoin investing in 2020 - was included last December under the index's technology sub-category. Strategy reported a net profit of $2.78 billion for the three months ended September 30, compared with a loss of $340.2 million a year earlier, mostly driven by an accounting change that allowed it to book gains on its bitcoin holdings.

Article Link

Why Analysts See Biogen’s Story Shifting Toward Undervalued Growth Potential

Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift reflects a cautiously constructive Street narrative that balances near term execution risks with growing confidence in longer term drivers such as Leqembi, the core neurology franchise, and late stage pipeline assets. Stay tuned to learn how you can track these evolving assumptions and the...

Article Link

Does Biogen’s Recent Share Price Rebound Reflect Its True Value in 2025?

If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the numbers are really saying. The stock has climbed 13.6% over the last month and is up 18.4% year to date, even though it is still down sharply over 3 and 5 years. That hints at a possible shift in how the market is reassessing its long term prospects and risk profile. Recent headlines have...

Article Link

3 Healthcare Stocks We Think Twice About

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 13.5%, nearly mirrorring the S&P 500.

Article Link